Daebongls.Co.,Ltd. reported earnings results for the second quarter and six months ended June 30, 2025. For the second quarter, the company reported sales was KRW 26,449.96 million compared to KRW 23,577.53 million a year ago. Net income was KRW 7,133.59 million compared to KRW 1,245.55 million a year ago. Basic earnings per share from continuing operations was KRW 652 compared to KRW 114 a year ago. Diluted earnings per share from continuing operations was KRW 565 compared to KRW 114 a year ago. Basic earnings per share was KRW 652 compared to KRW 114 a year ago. Diluted earnings per share was KRW 565.
For the six months, sales was KRW 0.00001 million compared to KRW 0.00001 million a year ago. Net income was KRW 9,872.15 million compared to KRW 2,229.41 million a year ago. Basic earnings per share from continuing operations was KRW 902 compared to KRW 204 a year ago. Diluted earnings per share from continuing operations was KRW 781 compared to KRW 204 a year ago. Basic earnings per share was KRW 902 compared to KRW 204 a year ago. Diluted earnings per share was KRW 781.
DaebongLS Co Ltd is a Korea-based company primarily engaged in the manufacture of pharmaceutical and cosmetic ingredients. The Company operates its business through two segments. The Pharmaceutical Active Ingredient Business segment provides active pharmaceutical ingredients for respiratory treatments, hypertension treatments, and digestive system treatments. The Cosmetic Material Business segment manufactures and sells natural and functional cosmetic ingredients. In addition, the Company provides testing services for materials used on the skin and engages in real estate leasing business. The Company sells its products in domestic and overseas markets.
